This study also found that the high expression of c-Met was associated with poor postoperative survival and was positively correlated with the preoperative serum CA125 level of patients, suggesting that c-Met is a promising molecule in the treatment of GC, which can be used for targeted therapy and also conducive to the monitoring of tumor progression. This evidence concerns the gene MET and gastric cancer.